What are the treatment options for locally advanced MDS

Treatment Options for Locally Advanced MDS

I appreciate your question, but I want to clarify an important distinction about MDS terminology that will help us discuss your situation more accurately.

Understanding MDS Classification

MDS (Myelodysplastic Syndromes) doesn't use the term "locally advanced" the way we use it for solid tumors like lung or breast cancer. MDS is a blood disorder affecting bone marrow cells throughout your entire body, so it's not staged by location.

Instead, MDS is classified by:

• Risk level (very low, low, intermediate, high)
• Blast percentage (the number of immature cells in bone marrow)
• Specific genetic mutations (changes in cancer-related genes)
• Cytogenetic abnormalities (chromosome changes)

How Risk Level Determines Treatment

According to the NCCN Guidelines for Myelodysplastic Syndromes (Version 1.2026), treatment approaches differ significantly based on disease risk:

Lower-Risk MDS (Very-Low, Low, or Intermediate-Risk)

Treatment focuses on managing symptoms and preventing progression:

Preferred approaches:

• Supportive care (blood transfusions, growth factors)
• Lenalidomide - if you have deletion 5q (a specific chromosome change)
• Imetelstat (Category 1 recommendation) - for anemia with ring sideroblasts
• Luspatercept (Category 1 recommendation) - for anemia when EPO levels are elevated
• Erythropoiesis-stimulating agents (ESAs) - to boost red blood cell production

Higher-Risk MDS

Treatment becomes more aggressive:

Primary options:

• Hypomethylating agents (HMAs):
  • Azacitidine
  • Decitabine
  • Decitabine and cedazuridine (oral combination)
• Targeted therapies (if specific mutations present):
  • Ivosidenib (for IDH1 mutations)
  • Enasidenib (for IDH2 mutations)
• Allogeneic hematopoietic cell transplantation (HCT) - bone marrow/stem cell transplant for eligible patients

Key Genetic Mutations That Guide Treatment

According to NCCN Guidelines, certain mutations help doctors decide on treatment:

• SF3B1 mutations - associated with ring sideroblasts and better prognosis; may respond well to imetelstat or luspatercept
• TP53 mutations - associated with poor prognosis; may need more aggressive treatment
• ASXL1, EZH2, RUNX1 mutations - independently associated with poor prognosis
• TET2 mutations - predict better response to hypomethylating agents

Questions to Ask Your Healthcare Team

Since your specific situation requires personalized evaluation, here are important questions:

1. What is my MDS risk category (very-low, low, intermediate, or high) based on my blast percentage, cytogenetics, and mutations?

2. What genetic mutations do I have, and how do they affect my treatment options?

3. What are the goals of treatment for my specific risk level—is it to manage symptoms, prevent progression, or pursue curative treatment?

4. Am I a candidate for allogeneic HCT, and if so, what would that involve?

5. What clinical trials might be appropriate for my specific mutation profile and risk level?

6. How will we monitor my response to treatment, and what would indicate we need to change approaches?

Why This Matters

The NCCN Guidelines emphasize that MDS is highly individualized. Your treatment plan depends on multiple factors working together—not just one finding. Your doctor will integrate your complete clinical picture (age, fitness for intensive treatment, comorbidities, specific mutations, and blast count) to recommend the best approach.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.